MTOR and neuroendocrine neoplasm: It should be noted that the genomic profile could not explain the variation in PFS observed in the everolimus monotherapy group; indeed, the two patients with the longest PFS, both with GI tract neuroendocrine tumors, had no mutations (ID 203) or no genomic alterations in the PI3K/AKT/mTOR pathway (ID 148), respectively.